[Effectiveness of 23-valent penumococcal polysaccharide and split-virus influenza vaccines to prevent respiratory diseases for elderly people].
OBJECTIVE
To assess the effectiveness of 23-valent penumococcal polysaccharide vaccine (PenV23) and Split-Virus influenza vaccine (InfV-B) for preventing upper respiratory diseases in the aging population.


METHODS
151 people aged > or =60 years who inoculated the PenV23 and InfV-B vaccines at clinics during 2005 as trial group, and 188 people aged > or =65 years didn't administered as control guoup from some comminity. On base line survey, both guoups were followed up two years after vaccination about incidence, hospitalization rate, treatment and direct medical cost.


RESULTS
The vaccine of PenV23 and InfV-B vaccination in upper respiratory tract infection was 60% [(odds ratio OR) = 0.35, 95% CI (0.153-0.794)] and the difference between the 2 groups was significant (P = 0.009). The people had recevied both vaccines, the mean duration of hospitalization in vaccinated vs unvaccinated control peple was 20.00 days: 24.19 days (t = 5.82, P < 0.001). Benefit-cost ratio was 4.03, and the net benefit was Yen 177994.86.


CONCLUSIONS
Incidence of influenza-like illness for the elderly people in the community decreased by administered PenV23 ahd InfV-B vaccine. This vaccines had high cost-benefits.
Wang
Mao-ci
MC
Rizhao Municipal Center for Disease Control and Prevention, Rizhao 276826 Shandong, China.
Wang
Tai-ping
TP
Yang
Shao-ming
SM
D000368:Aged; D000369:Aged, 80 and over; D000375:Aging / Q000276:immunology*; D016022:Case-Control Studies; D002681:China / Q000453:epidemiology; D003362:Cost-Benefit Analysis; D005260:Female; D005500:Follow-Up Studies; D006760:Hospitalization / Q000191:economics; D006801:Humans; D007252:Influenza Vaccines / Q000008:administration & dosage / Q000191:economics / Q000276:immunology*; D007251:Influenza, Human / Q000191:economics / Q000517:prevention & control*; D008297:Male; D008875:Middle Aged; D022242:Pneumococcal Vaccines / Q000008:administration & dosage / Q000191:economics / Q000276:immunology*; D012141:Respiratory Tract Infections / Q000191:economics / Q000453:epidemiology / Q000517:prevention & control* / Q000821:virology; D014611:Vaccination / Q000191:economics
C414006:23-valent pneumococcal capsular polysaccharide vaccine; D007252:Influenza Vaccines; D022242:Pneumococcal Vaccines